Neuropsychiatric events during prophylactic use of mefloquine before travelling

European Journal of Clinical Pharmacology

Volumn 58, Issue 6, 2002, Pages 441-445

  Van Riemsdijk, M ^a   Ditters, J ^b   Sturkenboom, M ^a   Tulen, J ^a   Ligthelm, R ^c   Overbosch, D ^c   Stricker, B ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Havenziekenhuis   (Netherlands)

Author keywords

Mefloquine; Neuropsychiatric events; Prophylaxis

Indexed keywords

MEFLOQUINE;

ADOLESCENT; ADULT; AFFECTIVE NEUROSIS; AGED; ANXIETY NEUROSIS; ARTICLE; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DYSPHORIA; FATIGUE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INSOMNIA; MALARIA; MALARIA CONTROL; MALE; NEUROPSYCHIATRY; PRIORITY JOURNAL; RATING SCALE; SEX DIFFERENCE; TRAVEL; VERTIGO;

ADOLESCENT; ADULT; AFFECTIVE DISORDERS, PSYCHOTIC; AGED; ANTIMALARIALS; CHILD; COHORT STUDIES; FEMALE; HUMANS; MALARIA; MALE; MEFLOQUINE; MIDDLE AGED; TRAVEL;

EID: 0036380414     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-002-0492-z     Document Type: Article

References (17)

1. Landelijke Coordinatiecentum Reizigersadvisering (1999) Malariaprofylaxe bulletin
2. Bem JL, Kerr L, Stuerchler D (1992) Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 95:167-179
3. Croft A, Garner P (1997) Mefloquine to prevent malaria: a systematic review of trials. BMJ 315:1412-1416
4. Sturchler D, Handschin J, Kaiser D, Kerr L, Mittelholzer ML, Reber R, et al (1990) Neuropsychiatric side effects of mefloquine. N Engl J Med 322:1752-1753
5. Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K, et al (1991) Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 45:86-91
6. Karbwang J, White NJ (1990) Clinical pharmacokinetics of mefloquine. Clin Pharmacokinet 19:264-279
7. van Riemsdijk MM, van der Klauw MM, van Heest JA, Reedeker FR, Ligthelm RJ, Herings RM, et al (1997) Neuropsychiatric effects of antimalarials. Eur J Clin Pharmacol 52:1-6
8. Schlagenhauf P, Steffen R, Lobel H, Johnson R, Letz R, Tschopp A, et al (1996) Mefloquine tolerability during chemoprophylaxis: focus on adverse event assessments, stereochemistry and compliance. Trop Med Int Health 1:485-494
9. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ (1996) Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: postal and telephone survey of travellers. BMJ 313:525-528
10. Davis TM, Dembo LG, Kaye-Eddie SA, Hewitt BJ, Hislop RG, Batty KT (1996) Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial. Br J Clin Pharmacol 42:415-421
11. Schlagenhauf P, Lobel H, Steffen R, Johnson R, Popp K, Tschopp A, et al (1997) Tolerance of mefloquine by SwissAir trainee pilots. Am J Trop Med Hyg 56:235-240
12. Wald FDM, Mellenbergh GJ (1990) De verkorte versie van de Nederlandse vertaling van de Profile of Mood States (POMS). Ned Tijdschr Psychol 45:86-90
13. Lim LY, Go ML (1985) The anticholinesterase activity of mefloquine. Clin Exp Pharmacol Physiol 12:527-531
14. Ngiam TL, Go ML (1987) Stereospecific inhibition of cholinesterases by mefloquine enantiomers. Chem Pharm Bull (Tokyo) 35:409-412
15. Hoover DB (1994) Cholinesterases and cholinesterase inhibitors. In: Craig CR, Stitzel RE (eds) Modern pharmacology, 4th edn. Little, Brown & Co., Boston
16. Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P, et al (1993) Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 341:1299-1303
17. Schwartz E, Potasman I, Rotenberg M, Almog S, Sadetzki S (2001) Serious adverse events of mefloquine in relation to blood level and gender. Am J Trop Med Hyg 65:189-192